Potential new drugs for human African trypanosomiasis: Some progress at last

Current Opinion in Infectious Diseases

Volumn 23, Issue 6, 2010, Pages 603-608

  Barrett, Michael P ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

diamidine; fexinidazole; human African trypanosomiasis; oxaborole; sleeping sickness

Indexed keywords

2,5 BIS(4 AMIDINOPHENYL)FURAN; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; ANTITRYPANOSOMAL AGENT; CPD 0802; DB 829; DB 868; DIAMIDINE DERIVATIVE; EFLORNITHINE; FEXINIDAZOLE; FURAMIDINE; MELARSOPROL; NIFURTIMOX; NITAZOXANIDE; NITROFURAL; PAFURAMIDINE; PENTAMIDINE; PHOSPHOGLUCONATE DEHYDROGENASE; SCYX 7158; UNCLASSIFIED DRUG;

AFRICAN TRYPANOSOMIASIS; ANTIPROTOZOAL ACTIVITY; BIOACCUMULATION; CHAGAS DISEASE; CLINICAL TRIAL; DRUG BRAIN LEVEL; DRUG EFFICACY; HELMINTHIASIS; HIGH THROUGHPUT SCREENING; HOSPITAL COST; HOSPITALIZATION COST; HUMAN; PNEUMOCYSTIS; PROTOZOAL INFECTION; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE; TRYPANOSOMA BRUCEI; TUBERCULOSIS;

ANIMALS; BENZAMIDES; BORON COMPOUNDS; DRUG DISCOVERY; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; EFLORNITHINE; HUMANS; MELARSOPROL; MICE; NIFURTIMOX; NITROIMIDAZOLES; PENTAMIDINE; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMIASIS, AFRICAN;

EID: 78349310347     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833f9fd0     Document Type: Review

References (46)

1. Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet 2010; 375:148-159.
2. Barrett MP, Burchmore RJ, Stich A, et al. The trypanosomiases. Lancet 2003; 362:1469-1480.
3. Barrett MP, Boykin DW, Brun R, Tidwell RR. Human African trypanosomiasis: pharmacological re-engagement with a neglected disease. Br J Pharmacol 2007; 152:1155-1171.
4. Williamson J. Chemotherapy of African trypanosomiasis. Trop Dis Bull 1976; 73:531-542.
5. Burri C, Baltz T, Giroud C, et al. Pharmacokinetic properties of the trypano-cidal drug melarsoprol. Chemotherapy 1993; 39:225-234.
6. Keiser J, Ericsson O, Burri C. Investigations of the metabolites of the trypanocidal drug melarsoprol. Clin Pharmacol Ther 2000; 67:478-488.
7. Burri C, Nkunku S, Merolle A, et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet 2000; 355:1419-1425.
8. Schmid C, Richer M, BilengeCM, et al. Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II). J Infect Dis 2005; 191:1922-1931.
9. Priotto G, Fogg C, Balasegaram M, et al. Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda. PLoS Clin Trials 2006; 1:e39.
10. Priotto G, KasparianS, NgouamaD, et al. Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo. Clin Infect Dis 2007; 45:1435-1442.
11. Priotto G, Kasparian S, Mutombo W, et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, noninferiority trial. Lancet 2009; 374:56-64.
12. Yun O, Priotto G, Tong J, et al. NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness. PLoS Negl Trop Dis 2010; 4:e720.
13. Paine MF, Wang MZ, Generaux CN, et al. Diamidines for human African trypanosomiasis. Curr Opin Investig Drugs 2010; 11:876-883.
14. Steck EA, Kinnamon KE, Davidson DE Jr, et al. Trypanosoma rhodesiense: evaluation of the antitrypanosomal action of 2,5-bis(4-guanylphenyl)furan dihydrochloride. Exp Parasitol 1982; 53:133-134.
15. Mathis AM, Holman JL, Sturk LM, et al. Accumulation and intracellular distribution of antitrypanosomal diamidine compounds DB75 and DB820 in African trypanosomes. Antimicrob Agents Chemother 2006; 50:2185-2191.
16. Wenzler T, Boykin DW, Ismail MA, et al. New treatment option for second-stage African sleeping sickness: in vitro and in vivo efficacy of aza analogs of DB289. Antimicrob Agents Chemother 2009; 53:4185-4192.
17. Filardi LS, Brener Z. A nitroimidazole-thiadiazole derivative with curative action in experimental Trypanosoma cruzi infections. Ann Trop Med Parasitol 1982; 76:293-297.
18. Bouteille B, Marie-Daragon A, Chauvière G, et al. Effect of megazol on Trypanosoma brucei brucei acute and subacute infections in Swiss mice. Acta Trop 1995; 60:73-80.
19. Barrett MP, Fairlamb AH, Rousseau B, et al. Uptake of the nitroimidazole drug megazol by African trypanosomes. Biochem Pharmacol 2000; 59:615-620.
20. Poli P, Aline de Mello M, Buschini A, et al. Cytotoxic and genotoxic effects of megazol, an anti-Chagas' disease drug, assessed by different short-term tests. Biochem Pharmacol 2002; 64:1617-1627.
21. Nesslany F, Brugier S, Mouriès MA, et al. In vitro and in vivo chromosomal aberrations induced by megazol. Mutat Res 2004; 560:147-158.
22. Wilkinson SR, Taylor MC, Horn D, et al. A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes. Proc Natl Acad Sci USA 2008; 105:5022-5027.
23. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimi-dazopyran drug candidate for the treatment of tuberculosis. Nature 2000; 405:962-966.
24. Anderson VR, Curran MP. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007; 67:1947-1967.
25. Jennings FW, Urquhart GM. The use of the 2 substituted 5-nitroimidazole, fexinidazole (Hoe 239) in the treatment of chronic T brucei infections in mice. Z Parasitenkd 1983; 69:577-581.
26. Sokolova AY, Wyllie S, Patterson S, et al. Cross-resistance to nitro drugs and implications for treatment of human African trypanosomiasis. Antimicrob Agents Chemother 2010; 54:2893-2900.
27. Raether W, Seidenath H. The activity of fexinidazole (HOE 239) against experimental infections with Trypanosoma cruzi, trichomonads and Entamoe-ba histolytica. Ann Trop Med Parasitol 1983; 77:13-26.
28. Baliani A, Bueno GJ, Stewart ML, et al. Design and synthesis of a series of melamine-based nitroheterocycles with activity against Trypanosomatid parasites. J Med Chem 2005; 48:5570-5579.
29. Hall BS, Wu X, Hu L, Wilkinson SR. Exploiting the drug-activating properties of a novel trypanosomal nitroreductase. Antimicrob Agents Chemother 2010; 54:1193-1199.
30. Frearson JA, Wyatt PG, Gilbert IH, Fairlamb AH. Target assessment for antiparasitic drug discovery. Trends Parasitol 2007; 23:589-595.
31. Price HP, Menon MR, Panethymitaki C, et al. Myristoyl-CoA:protein N-myr-istoyltransferase, an essential enzyme and potential drug target in kinetoplas-tid parasites. J Biol Chem 2003; 278:7206-7214.
32. Frearson JA, Brand S, McElroy SP, et al. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness. Nature 2010; 464:728-732.
33. Smithson DC, Lee J, Shelat AA, et al. Discovery of potent and selective inhibitors of Trypanosoma brucei ornithine decarboxylase. J Biol Chem 2010; 285:16771-16781.
34. Ojo KK, Gillespie JR, Riechers AJ, et al. Glycogen synthase kinase 3 is a potential drug target for African trypanosomiasis therapy. Antimicrob Agents Chemother 2008; 52:3710-3717.
35. Sharlow ER, Lyda TA, Dodson HC, et al. A target-based high throughput screen yields Trypanosoma brucei hexokinase small molecule inhibitors with antiparasitic activity. PLoS Negl Trop Dis 2010; 4:e659.
36. Ruda GF, Campbell G, Alibu VP, et al. Virtual fragment screening for novel inhibitors of 6-phosphogluconate dehydrogenase. Bioorg Med Chem 2010; 18:5056-5062.
37. Cuatrecasas P. Drug discovery in jeopardy. J Clin Invest 2006; 116:2837-2842.
38. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008; 4:682-690.
39. Boran AD, Iyengar R. Systems approaches to polypharmacology and drug discovery. Curr Opin Drug Discov Dev 2010; 13:297-309.
40. Räz B, Iten M, Grether-Bühler Y, et al. The Alamar Blue assay to determine drug sensitivity of African trypanosomes (T. b. rhodesiense and T b. gam-biense) in vitro. Acta Trop 1997; 68:139-147.
41. Mackey ZB, Baca AM, Mallari JP, et al. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem Biol Drug Des 2006; 67:355-363.
42. Drewry DH, Macarron R. Enhancements of screening collections to address areas of unmet medical need: an industry perspective. Curr Opin Chem Biol 2010; 14:289-298.
43. Damper D, Patton CL. Pentamidine transport in Trypanosoma brucei: kinetics and specificity. Biochem Pharmacol 1976; 25:271-276.
44. Haanstra JR, van Tuijl A, Kessler P, et al. Compartmentation prevents a lethal turbo-explosion of glycolysis in trypanosomes. Proc Natl Acad Sci USA 2008; 105:17718-17723.
45. Hornberg JJ, Bruggeman FJ, Bakker BM, Westerhoff HV. Metabolic control analysis to identify optimal drug targets. Prog Drug Res 2007; 64:173-189.
46. Bakker BM, Krauth-Siegel RL, Clayton C, et al. The silicon trypanosome. Parasitology 2010; 137:1333-1341.